Attached files

file filename
EX-32.1 - EXHIBIT 32.1 CERTIFICATION OF CEO PURSUANT TO 18 USC - INTEGRATED BIOPHARMA INCex_202528.htm
EX-31.2 - EXHIBIT 31.2 CERTIFICATION OF CFO - INTEGRATED BIOPHARMA INCex_202527.htm
EX-31.1 - EXHIBIT 31.1 CERTIFICATION OF CEO - INTEGRATED BIOPHARMA INCex_202526.htm
EX-23.1 - EXHIBIT 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - INTEGRATED BIOPHARMA INCex_202530.htm
EX-10.221 - EXHIBIT 10.22.1 AMENDMENT TO PAYCHECK PROTECTION PROGRAM TERM NOTE - INTEGRATED BIOPHARMA INCex_204539.htm
EX-21 - EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT - INTEGRATED BIOPHARMA INCex_202531.htm
10-K - FORM 10-K - INTEGRATED BIOPHARMA INCinbp20200630_10k.htm

Exhibit 32.2

 

 

CERTIFICATION OF PERIODIC REPORT

 

As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Annual Report on Form 10-K for the fiscal year ended June 30, 2020 of Integrated BioPharma, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Dina L. Masi, the Senior Vice President and Chief Financial Officer of Integrated BioPharma, Inc. (the "Company"), certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to her knowledge:

 

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended.

 

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

Date: September 23, 2020

By: /s/ Dina L. Masi

 

Dina L. Masi

 

Senior Vice President and Chief Financial Officer